Pediatrix Medical Group, Inc.
🔔 Watch stock
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
Why this colour
Whoever buys today is betting that the reimbursement gains carry the results until volumes turn — and that the Medicaid cuts depress rates more slowly than management can renegotiate. Whoever waits will find two simple markers in the coming quarterly reports: do patient volumes swing back to growth, and does the payor mix stay stable? The next report is scheduled for August 4, 2026. The decision is yours.
What the thesis turns on
Assessment: Opportunities & Risks
Pediatrix is a successful turnaround with a chronic underlying condition: adjusted operating profit has grown for two consecutive years, the balance sheet is nearly debt-free on a net basis, and the NICU network holds a market position that cannot be copied. But more than half the bills go to government programs that pay substantially less and are being cut by law since July 4, 2025, patient volumes just shrank, and 70 cents of every revenue dollar are tied up in physician pay. After an 81 percent rally, a good part of the recovery is already paid for — insiders sold while analysts recommend buying. Not investment advice.
Business model & market position
The largest neonatology network in the U.S.: 1,350 of the country's roughly 7,200 board-certified neonatologists, more than 360 staffed and managed NICUs in 32 states, long-standing hospital contracts — an asset-light business with high barriers to entry (annual report 10-K for 2025).
Turnaround & cash flow
Adjusted EBITDA up two years in a row ($200.4 → $224.0 → $275.6 million, 2023–2025), net income of $165.4 million after two loss years, Q1 2026 up 43 percent; operating cash flow of $274.7 million against $18.5 million of capex, cash nearly covers the debt, a $250 million buyback program is running.
Payor structure & politics
About 53 percent of gross billings go to government programs that per the report pay "substantially less" (only 24 percent of net revenue); the One Big Beautiful Bill Act of July 4, 2025 cuts Medicaid with a possible "material impact" per the report; the No Surprises Act categorically bans balance billing in neonatology; Texas bundles 32 percent of revenue.
Volumes & demographics
The U.S. birth rate is in structural decline per the risk factors; same-unit patient volumes fell 1.6 percent in the first quarter of 2026 (maternal-fetal medicine and neonatology) — growth came entirely from reimbursement and collection factors (+4.4 percent) that cannot be repeated at will; 70.1 percent of revenue is tied up in practice salaries.
Valuation & signals
P/E around 12, price-to-free-cash-flow around 8, EV/adjusted EBITDA around 7.5 — moderate for the quality, but after an 81 percent twelve-month rally no longer a crisis price; analyst consensus (8 houses) on the buy side against three insider sales without a single purchase, fundamental grade C and a Piotroski score of 6 of 9 (data as of July 10, 2026).
Worth Noting
MD reached our research list via the Reddit hype scanner (ApeWisdom, 2 mentions in 24 hours, as of July 15, 2026) — still listed there under the name "Mednax", retired in 2022; the identity was verified via the SEC register (CIK 0000893949, former names).
The 15 hits in our in-house stock scanner carry the July 10, 2026 data cut-off and rotate daily; scanner metrics are computed from trailing twelve-month figures and reflect Q1 2026 effects only with a lag.
Price and valuation figures are dated to July 10, 2026 (about $24, market value roughly $1.95 billion); analyses are evergreen, daily prices are not a buy argument.
Stock Watch
This analysis is as of August 26, 2026. Stock Watch will tell you what's changed at MD since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 15.80 $ to 27.40 $ · Last price: 25.50 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Medical Care Facilities
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Pediatrix Medical Group, Inc. MD | 2.1 | 12.8 | 8.4 | 26.2 | 9.8 | -4.9 | 57.5 |
| HCA Healthcare, Inc. HCA | 95.2 | 15.2 | 9.0 | 42.6 | 15.0 | 7.1 | 8.2 |
| Tenet Healthcare Corporation THC | 22.6 | 14.0 | 5.8 | 41.7 | 17.9 | 3.1 | 42.8 |
| Encompass Health Corp EHC | 12.2 | 21.3 | 9.8 | 43.9 | 19.0 | 10.5 | -0.2 |
| DaVita HealthCare Partners Inc DVA | 11.7 | 18.1 | 8.9 | 32.4 | 13.9 | 6.5 | 43.0 |
| Universal Health Services Inc UHS | 10.9 | 7.9 | 5.5 | 44.6 | 11.2 | 9.7 | -3.1 |
| The Ensign Group Inc ENSG | 10.2 | 29.2 | 19.3 | 16.6 | 9.0 | 18.7 | 5.6 |
| Chemed Corp CHE | 6.7 | 29.8 | 15.7 | 33.1 | 12.9 | 4.1 | 11.2 |
| PACS Group, Inc. PACS | 6.5 | – | 20.3 | 17.3 | 8.5 | 29.3 | 274.9 |
| Median of companies shown | 10.9 | 16.7 | 9.0 | 33.1 | 12.9 | 7.1 | 11.2 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 3,183 | 572 | 325 | 3.47 | 444 | 2,761 | 5,339 |
| 2017 | 3,458 | 480 | 320 | 3.42 | 511 | 3,066 | 5,867 |
| 2018 | 3,647 | 446 | 269 | 2.93 | 290 | 3,088 | 5,935 |
| 2019 | 1,780 | 172 | -1,498 | -17.78 | 347 | 1,499 | 4,146 |
| 2020 | 1,734 | 98 | -796 | -9.31 | 205 | 747 | 3,348 |
| 2021 | 1,911 | 203 | 131 | 1.52 | 77 | 896 | 2,723 |
| 2022 | 1,972 | 173 | 66 | 0.79 | 167 | 892 | 2,348 |
| 2023 | 1,995 | 7 | -60 | -0.73 | 137 | 849 | 2,220 |
| 2024 | 2,013 | -69 | -99 | -1.19 | 207 | 765 | 2,153 |
| 2025 | 1,914 | 231 | 165 | 1.94 | 271 | 866 | 2,247 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.35 | – | 502 | 1.20 | 6.10 | 133 | 130 |
| 2025: Q1 | 0.24 | 398.70 | 458 | -7.40 | 4.50 | -118 | -121 |
| 2025: Q2 | 0.45 | – | 469 | -7.00 | 8.40 | 137 | 133 |
| 2025: Q3 | 0.84 | 264.20 | 493 | -3.60 | 14.50 | 137 | 132 |
| 2025: Q4 | 0.40 | 12.40 | 494 | -1.70 | 6.80 | 114 | 109 |
| 2026: Q1 | 0.36 | 47.30 | 476 | 3.90 | 6.20 | -130 | -136 |
| 2026: Q2 | 0.49 | 8.90 | 488 | 4.10 | 8.20 | 125 | 125 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 16 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
- 21-EMA Trend
- Above 21-EMA Pullback
- Above the 50- & 200-SMA
- Gary Antonacci: Dual Momentum (Stock Adaptation)
- Mark Minervini: Trend Criteria — 1 Month
- Near 52-Week High
- Power Trend
- Stan Weinstein: Stage 2
Research
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.35 | 2.26 – 2.40 | 1,961 | 15.1% | 7 |
| 12/31/2027 | 2.44 | 2.25 – 2.59 | 2,009 | 3.9% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly -3.3% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $229.0M |
|---|---|
| Market cap | $2.06B |
| Free cash flow in year ten | $163.1M |
| Terminal value as a share of market value | 41.6% |
For comparison: over the past five years free cash flow grew by 7.5% per year.
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Pediatrix setzt KI laut Geschäftsbericht (10-K für 2025) operativ ein — die eigenen Informationssysteme für Tagesbetrieb, klinische Initiativen und Geschäftsanalysen nutzen zunehmend KI, insbesondere zur Unterstützung der klinischen Dokumentation; das elektronische Patientenakten-System enthält KI-Werkzeuge für die Arzt-Dokumentation. KI-Produkte sind keine Umsatzquelle, und ein konkretes KI-Risiko für das Geschäftsmodell (Arztleistungen in Neugeborenen-Intensivstationen) benennen die Filings nicht — nur die generischen Einsatz- und Wettbewerbsrisiken der eigenen Nutzung.
View the full file — quotes, sources, reviewed filings
„Some of our information systems that support our day-to-day operations, ongoing clinical initiatives and business analyses increasingly utilize AI, including to assist with clinical documentation. AI technologies are highly complex and rapidly evolving, and their use presents risks, challenges and the potential for unintended consequences, including errors, bias, system failures, or limitations in performance, which could affect their adoption or effectiveness and, in turn, our operations and business."
Einige unserer Informationssysteme, die unseren Tagesbetrieb, laufende klinische Initiativen und Geschäftsanalysen unterstützen, nutzen zunehmend KI — unter anderem zur Unterstützung der klinischen Dokumentation. KI-Technologien sind hochkomplex und entwickeln sich rasant; ihr Einsatz birgt Risiken, Herausforderungen und das Potenzial unbeabsichtigter Folgen, darunter Fehler, Verzerrungen, Systemausfälle oder Leistungsgrenzen, die ihre Einführung oder Wirksamkeit und damit unseren Betrieb und unser Geschäft beeinträchtigen könnten.
10-K · 2026-02-19 · View SEC filing
„This product line provides additional benefits to our ambulatory practices, including clinical decision trees to assist physicians with the selection of compliant billing codes, medication management (including electronic prescription of controlled substance and prescription drug monitoring programs), promotion of consistent documentation, patient engagement tools, virtual visits and telemedicine tools, Artificial intelligence tools for streamlined clinician documentation, a new referral management template, and data for research and education."
Diese Produktlinie bietet unseren ambulanten Praxen zusätzliche Vorteile, darunter klinische Entscheidungsbäume zur Unterstützung der Ärzte bei der Auswahl regelkonformer Abrechnungscodes, Medikamentenmanagement (einschließlich elektronischer Verschreibung kontrollierter Substanzen und Programmen zur Überwachung verschreibungspflichtiger Arzneimittel), Förderung einer einheitlichen Dokumentation, Werkzeuge zur Patienteneinbindung, virtuelle Visiten und Telemedizin-Werkzeuge, Künstliche-Intelligenz-Werkzeuge für eine gestraffte Dokumentation der Kliniker, eine neue Vorlage für das Überweisungsmanagement sowie Daten für Forschung und Lehre.
10-K · 2026-02-19 · View SEC filing
„At the same time, our ability to remain competitive may depend in part on our ability to effectively develop, implement and utilize AI technologies. If we are unable to keep pace with technological developments or the adoption of AI by competitors, or if competitors are able to achieve greater operational efficiencies, cost savings, or service enhancements through their use of AI, our competitive position, operating results, or growth prospects could be adversely affected."
Zugleich kann unsere Wettbewerbsfähigkeit teilweise davon abhängen, ob wir KI-Technologien wirksam entwickeln, einführen und nutzen können. Sollten wir mit der technologischen Entwicklung oder der KI-Einführung durch Wettbewerber nicht Schritt halten, oder sollten Wettbewerber durch ihren KI-Einsatz größere operative Effizienzgewinne, Kosteneinsparungen oder Leistungsverbesserungen erzielen können, könnten unsere Wettbewerbsposition, unser Betriebsergebnis oder unsere Wachstumsaussichten beeinträchtigt werden.
10-K · 2026-02-19 · View SEC filing
Filings Reviewed: 10-Q 2026-05-05 · 10-Q 2025-11-03 · 10-Q 2025-08-05 · 10-Q 2025-05-06 · 10-K 2026-02-19 · 10-K 2025-02-20
Rated on July 16, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -1.0%
- More than 10% revenue growth is expected for the coming year 2.5%
- Share count grows by less than 3% a year 0.5%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 8.3%
- Gross margin at 40% or higher and without meaningful erosion 24.7%
- Goodwill from acquisitions does not grow faster than revenue 56.1%
- Net debt below twice EBITDA 0.6 x EBITDA
- Operating cash flow covers the profits of the last three years 609 m
- Return on capital at 15% or higher, or up versus two years ago 12.9%
- Insiders hold at least 10% or are net buyers 2.0%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -5.5%
- Exp. sales growth 3Y > 5% 2.5%
- EBIT growth 10Y > 5% -9.6%
- Exp. EBIT growth 3Y > 5% 12.2%
- Net debt < 4x EBIT 0.7x
- EBIT positive, 10Y straight 9
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% –
- ROCE > 15% 12.9%
- Expected return > 10% 25.9%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Linynsky Laura A | Director | Other | 6,000 | 26.82 | 160,920 |
| Aug 14, 2026 | Young Sylvia Jean | Director | Other | 18,500 | 26.62 | 492,470 |
| Aug 12, 2026 | McEachin Thomas | Director | Other | 472 | 26.50 | 12,508 |
| Aug 12, 2026 | Weis Shirley A | Director | Other | 472 | 26.50 | 12,508 |
| Aug 12, 2026 | Starcher John M. Jr. | Director | Other | 472 | 26.50 | 12,508 |
| Aug 12, 2026 | Newman Kurt Douglas | Director | Other | 472 | 26.50 | 12,508 |
| Aug 12, 2026 | Linynsky Laura A | Director | Other | 472 | 26.50 | 12,508 |
| Aug 12, 2026 | Rucker Michael A. | Director | Other | 472 | 26.50 | 12,508 |
| Aug 12, 2026 | Young Sylvia Jean | Director | Other | 472 | 26.50 | 12,508 |
| Aug 12, 2026 | Sansone Guy P | Director | Other | 472 | 26.50 | 12,508 |
The company
About the Company
Pediatrix Medical Group, Inc. bietet gemeinsam mit ihren Tochtergesellschaften Versorgungsdienste für Neugeborene, Maternal-Fetal-Medizin und andere pädiatrische Subspezialitäten in den USA an.
- CEO Insider Trades (12 Mo.)
- selling own stock
- Employees
- 4,280
- Headquarters
- Sunrise, FL
- Address
- 1301 Concord Terrace, 33323 Sunrise, United States
- Phone
- 954 384 0175
- Website
- pediatrix.com
- IPO Date
- 09/19/1995
- ISIN
- US58502B1061
- Stock Split
- 2:1 on 12/20/2013
- Stock Split
- 2:1 on 04/28/2006
Management
| Name | Title | Birth Year |
|---|---|---|
| Mark S. Ordan | CEO & Executive Chairman | 1959 |
| Kasandra H. Rossi | Executive VP, Treasurer & CFO | 1973 |
| D. Gregory Neeb | Executive VP & Chief Operating and Strategy Officer | 1968 |
| Mary Ann E. Moore J.D. | Advisor | 1960 |
| John C. Pepia | Senior VP & Chief Accounting Officer | 1963 |
| Cheryl M. VanPatten | Senior VP & Chief Information Officer | – |
| David Haddock | Executive Vice President, General Counsel & Secretary | – |
| Debra McRoberts | Senior Vice President of People Services | – |
| Kevin Pitzer | President of West Division | – |
| Mike Ashford | President of South Central Division | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/04/2026 Pediatrix Medical Group, Inc. (MD): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 07/24/2026 Pediatrix Medical Group, Inc. (MD): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure SEC ↗
- 07/15/2026 Pediatrix Medical Group, Inc. (MD): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.